Q-omics provides the consensus-scored XPNPEP3 profile across patient tissues and cancer cell-line models. XPNPEP3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, XPNPEP3 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, XPNPEP3 RNA expression shows 20,666 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight READ, COAD, and ACC as cancer lineages where XPNPEP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for XPNPEP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes XPNPEP3 survival associations across molecular data types. XPNPEP3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible XPNPEP3 RNA expression–survival associations across cancer types. High XPNPEP3 expression shows unfavorable associations in LUAD, UVM, KIRP and THCA, but favorable associations in READ and LUSC. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for XPNPEP3 RNA expression.
This table summarizes XPNPEP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for XPNPEP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. XPNPEP3 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, BLCA, LIHC and LUAD. The COAD box plot shows higher XPNPEP3 RNA expression in tumor versus normal tissue (log2 FC = +1.101, t-test p < 0.001).
This table shows molecular features associated with XPNPEP3 in patient tissues and cancer cell lines. In patient samples, XPNPEP3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, XPNPEP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
